Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the third quarter ended September 30, 2008.

"We continue to make rapid progress in both of our hepatitis C development programs," said Steve Worland Ph.D., President and CEO of Anadys. "We completed our first clinical study of ANA598 in healthy volunteers and have now completed the healthy volunteer portion of our ongoing ANA773 study. For both programs, we are very encouraged by the data and look forward to initiating patient dosing this quarter."

Financial Results

As of September 30, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $34.4 million.

During the third quarter of 2008 the Company had no revenue, compared to $21.5 million for the same quarter of 2007. The revenue in the third quarter of 2007 was primarily derived from the recognition of previously deferred revenue associated with an upfront payment and a milestone payment under a prior collaboration.

Research and development expenses were $7.6 million for the third quarter of 2008 and 2007. During the third quarter of 2008, cost savings derived from Anadys' completed strategic restructuring and associated termination of prior development programs were offset by a significant increase in ANA598 development costs.

General and administrative expenses were $2.1 million for the third quarter of 2008, compared to $2.4 million for the third quarter of 2007. The $0.3 million decrease primarily resulted from cost savi
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... solution to one of the key challenges in the ... of Sussex physicists. , In a paper published today ... Garraway and colleagues show how to make a new ... Quantum technology devices, such as high-precision sensors and specialised ... of atoms. But the methods for trapping these tiny ...
(Date:10/27/2014)... Ryan Carfley , Managing Partner at ... down with Bryan Hamilton, the publisher of the Triangle Business ... in the Research Triangle region of North Carolina. , Just ... the roundtable include the role of social media in ... balance and the unique role that Millennials play in the ...
(Date:10/27/2014)... The Italian company Roadrunnerfoot ... sell its artificial "lower limb", after the German ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) , ... definitive judgement has arrived: Roadrunnerfoot, the small Italian ... hi-tech prostheses with composite materials, has won against ...
(Date:10/27/2014)... YORK , Oct. 27, 2014 Kalorama ... the recent Ebola concern in the United ... the virus.  The healthcare market researcher said the FDA,s Emergency ... in vitro diagnostic tests for the detection of the ... has proved useful.  Kalorama routinely assess the IVD industry ...
Breaking Biology Technology:Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... Inc. (NYSE: CRY ), an implantable biological medical ... it has filed an IDE with the United States ... the purpose of obtaining Pre-Market Approval (PMA) to distribute PerClot ... following traumatic injuries. PerClot is a unique, ...
... EMERYVILLE, Calif., April 4, 2011 Newly proposed ... patient care under healthcare reform closely mirror quality ... the American healthcare system, a MedeAnalytics analysis has ... The quality measure analysis is included ...
... April 4, 2011 Techne Corporation (NASDAQ: ... April 1, 2011, its R&D Systems subsidiary has ... leading developer and manufacturer of innovative ubiquitin-related research ... that facilitate and accelerate basic research and drug ...
Cached Biology Technology:CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 2CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 3CryoLife Files Investigational Device Exemption (IDE) to Begin Clinical Trials for PerClot® in the U.S. 4ACO Proposed Rule: Nine out of Ten Quality Measures Mirror Other Quality Reporting Programs 2Techne Corporation Announces Acquisition 2Techne Corporation Announces Acquisition 3Techne Corporation Announces Acquisition 4
(Date:10/28/2014)... Health (NIH) announced awards to expand the Office ... Center for Advancing Translational Sciences (ORDR-NCATS) collaborative Rare ... network, physician scientists at 22 consortia will work ... research and investigate new treatments for patients with ... $29 million in fiscal 2014 funding from NIH. ...
(Date:10/28/2014)... in a novel environment are linked to individual ... experimental study completed at the University of Eastern ... Institute. The study used novel, long-term observations of ... to analyse if behaviours predict the vulnerability to ... enriched hatchery rearing environments. Based on the ...
(Date:10/28/2014)... associated with a lower risk of developing ovarian cancer, ... Anglia (UEA). , Research published today reveals that ... subclasses of dietary flavonoids) significantly decrease their risk of ... death among women. , The research team studied ... and 55 for more than three decades. , ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Fish 'personality' linked to vulnerability to angling 2Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2
... for a University of Alberta paleontology researcher, who after months of ... as a new species of pterosaur, a flying reptile that lived ... stumped when the small piece of jaw bone was first pulled ... A,s paleontology department. "It could have been from a dinosaur, ...
... 4, 2011) − Scientists at the University of Kentucky have ... break up blood clots, speeds up the progress of prion ... plasminogen a promising new target for the development of drugs ... senior author Chongsuk Ryou, a researcher at the UK Sanders-Brown ...
... Lithuania, Jan. 10, 2011 Neurotechnology , ... announced the release of MegaMatcher 4.0 , ... fingerprint, iris, facial and palmprint biometrics in a ... MegaMatcher 4.0, Neurotechnology has incorporated palmprint technology along ...
Cached Biology News:Research identifies drug target for prion diseases, 'mad cow' 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 3
... PROTEAN II xi cell, 16 cm, is used ... and proteins in agarose gels. The cell is ... a central cooling core with gaskets, lower buffer ... plates, 4 sandwich clamps, upper buffer dam, casting ...
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
...
... system uses the Adept CE 4100 high pressure ... dual wavelength detector for added flexibility. ... processing software and interface unit, CE 4901., The ... may also be used with Windows 98 and ...
Biology Products: